General characteristics
| Male, n (total) | 8 (12) |
| Age (years) | 74±8 |
| BSA (m2) | 1.9±0.2 |
| Hypertension, n (%) | 8 (8%) |
| Diabetes, n (%) | 2 (80%) |
| Dyslipidaemia, n (%) | 2 (20%) |
| NYHA functional class | 1 (1, 2) |
| Electrocardiography | |
| PR duration (ms) | 135 (130, 135) |
| QRS duration (ms) | 111 (104, 118) |
| Percentage of pacing (%) | 14±4 |
| Echocardiography | |
| LV end-diastolic volume indexed (mL/m2) | 67±11 |
| LV end-systolic volume indexed (mL/m2) | 28±6 |
| LV ejection fraction (%) | 58±6 |
| LAVi (mL/m2) | 32±14 |
| TAPSE (mm) | 22±2 |
| PAPs (mm Hg) | 36±7 |
| E/A ratio | 0.68±0.1 |
| E/e' ratio | 6.12±1.2 |
| Medications | |
| ARBs (%) | 7 (70) |
| Loop diuretics (%) | 1 (10) |
| Antiplatelet (%) | 8 (80) |
| Statins (%) | 2 (20) |
| Antidiabetic drugs (%) | 3 (30) |
Data are described as mean (±SD) or median (IQR) for quantitative variables, and counts (proportions) for categorical variables.
ARBs, angiotensin receptors blockers; BSA, body surface area; EF, ejection fraction; LAVi, left atrial volume index; LV, left ventricle; PAPs, systolic pulmonary arterial pressure ; TAPSE, tricuspid annular plane systolic excursion.